Clinical trial design, endpoints and regulatory considerations in heart failure
Following the withdrawal of flosequinan in the early 1990s due to heightened mortality and fatal arrhythmia risks, regulatory agencies have demanded evidence of the efficacy of novel treatments in managing heart failure, with mortality and morbidity endpoints becoming more stringent criteria for ap...
Zapisane w:
| 1. autor: | |
|---|---|
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
PAGEPress Publications
2024-03-01
|
| Seria: | Global Cardiology |
| Hasła przedmiotowe: | |
| Dostęp online: | https://www.globalcardiology.info/site/article/view/18 |
| Etykiety: |
Nie ma etykietki, Dołącz pierwszą etykiete!
|